Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | FNTA | P49354 | 2/20 | 0.47 |
| ▸ | FNTB | P49356 | 2/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334144 | 1.00 | POLB (0.52) | POLBCNR2FNTAFNTBPGGT1B | |
| SCHEMBL2330757 | 0.90 | PPID (0.55) | POLBCNR2FNTAFNTBPGGT1B | |
| SCHEMBL2330760 | 0.90 | PPID (0.55) | POLBCNR2FNTAFNTBPGGT1B | |
| SCHEMBL2328031 | 0.87 | L3MBTL1 (0.56) | POLBFNTAFNTBPGGT1BL3MBTL1 | |
| SCHEMBL2328029 | 0.87 | L3MBTL1 (0.56) | POLBFNTAFNTBPGGT1BL3MBTL1 | |
| SCHEMBL4422071 | 0.85 | POLB (0.52) | POLBCNR2FNTAFNTBPGGT1B | |
| SCHEMBL6136477 | 0.85 | POLB (0.52) | POLBCNR2FNTAFNTBPGGT1B | |
| SCHEMBL2331099 | 0.83 | FNTA (0.61) | POLBCNR2FNTAFNTBPGGT1B | |
| SCHEMBL2331097 | 0.83 | FNTA (0.61) | POLBCNR2FNTAFNTBPGGT1B | |
| SCHEMBL2328066 | 0.83 | POLB (0.51) | POLBCNR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835498-B2 | Anti-wrinkle agents | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| CN-102215812-B | Anti-wrinkle agents | POLA CHEM IND INC | 2014-09-10 | — | — | CN | disclosed |
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-2356979-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | GLA, H1-4, H1-3 | POLB 1044/4885CNR2 1779/4885FNTA 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.